

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-22 (Canceled)

Claim 23 (Currently amended): A method of treating an individual suspected of suffering from metastatic colorectal cancer comprising the step of administering to said individual a therapeutically effective amount of a pharmaceutical composition that comprises:

- a) an ST receptor ligand;
- b) an active agent, wherein the active agent causes cell death; and
- c) a pharmaceutically acceptable carrier or diluent;

wherein said ST receptor ligand is an antibody, FAb or F(Ab)₂.

Claims 24-27 (Canceled)

Claim 28 (Currently amended): The method of claim 23 ~~27~~ wherein said ST receptor ligand is an antibody.

Claim 29 (Previously added): The method of claim 23 wherein said active agent is a cytotoxic agent.

Claim 30 (Currently amended): The method of claim 29 wherein said active agent is selected from the group consisting of methotrexate, doxorubicin, daunorubicin,

cytosinarabioside, etoposide, 5-fluorouracil ~~5-4-fluorouracil~~, melphalan, chlorambucil, *cis*-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain, *Pseudomonas* exotoxin, diphtheria toxin, *Clostridium perfringens* phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, modeccin, viscumin, volkensin, nitroimidazole, metronidazole and misonidazole.

Claims 31-35 (Canceled)

C5
Claim 36 (Previously added): The method of claim 23 wherein said pharmaceutical composition is administered intravenously.

Claims 37-49 (Canceled)

Claim 50 (New): The method of claim 30 wherein said ST receptor ligand is an antibody.

51 (New): The method of claim 36 wherein said ST receptor ligand is an antibody.

52 (New): The method of claim 23 wherein said ST receptor ligand is a FAb.

53 (New): The method of claim 30 wherein said ST receptor ligand is a FAb.

DOCKET NO.: TJU-2444
Application No.: 09/724,983
Office Action Dated: December 31, 2002

PATENT

54 (New): The method of claim 36 wherein said ST receptor ligand is a FAb.

C5
55 (New): The method of claim 23 wherein said ST receptor ligand is a F(Ab)₂.

56 (New): The method of claim 30 wherein said ST receptor ligand is a F(Ab)₂.

57 (New): The method of claim 36 wherein said ST receptor ligand is a F(Ab)₂.
